Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions
Vaccine, Volume 32, No. 17, Year 2014
Notification
URL copied to clipboard!
Description
Background: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type b vaccines were transitioned to a combined pentavalent vaccine. The current schedule offers three doses of PCV and pentavalent, and continues to give children monovalent hepatitis B vaccine at birth. We estimated the overall costs of the Gambian immunisation programme and the incremental costs of introducing pentavalent and the seven-valent PCV. Methods: Twenty health facilities out of a total of 56 were surveyed. Data collected included number of vaccine doses delivered, staff time spent on vaccine delivery, distance travelled to collect vaccines, and cold chain expansion due to new vaccine introduction. National level data were collected from key informant interviews. Annualised costs were calculated in 2009 US$. Results: With a PCV price of US$7 per dose, the incremental costs of introducing PCV was US$1.6 million, equivalent to US$25 per fully immunised child, with systems costs accounting for US$1.90. The switch to pentavalent vaccine resulted in cost savings of US$0.45 per fully immunised child. Total annual costs increased by 45% after the introduction of the new vaccines, amounting to US$ 3.0 million, or US$45 per fully immunised child. Conclusion: Vaccine prices were the most important determinant of total incremental costs and cold chain expansion the biggest cost component of systems costs. © 2014 Elsevier Ltd.
Authors & Co-Authors
Usuf, Effua Abigail
Unknown Affiliation
MacKenzie, Grant Austin
Unknown Affiliation
Lowe Jallow, Yamundow
Unknown Affiliation
Boye, B.
Unknown Affiliation
Atherly, Deborah E.
Unknown Affiliation
Suraratdecha, Chutima
Unknown Affiliation
Griffiths, Ulla Kou
Unknown Affiliation
Statistics
Citations: 24
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1016/j.vaccine.2014.01.045
ISSN:
0264410X
e-ISSN:
18732518
Research Areas
Infectious Diseases
Maternal And Child Health
Study Locations
Gambia